Articles

Articles 5,464 registres trobats  inicianterior351 - 360següentfinal  anar al registre: La cerca s'ha fet en 0.00 segons. 
351.
19 p, 600.4 KB Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Barrientos, Jacqueline C. (Zucker School of Medicine at Hofstra/Northwell) ; O'Brien, Susan (University of California Irvine) ; Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Kay, Neil E. (Mayo Clinic) ; Reddy, Nishitha M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E (Stanford University School of Medicine) ; Tam, Constantine (Peter MacCallum Cancer Centre and St Vincent's Hospital) ; Mulligan, Stephen (Royal North Shore Hospital) ; Jaeger, Ulrich (Medical University of Vienna) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; Pocock, Christopher (East Kent Hospitals University) ; Robak, Tadeusz (Medical University of Lodz) ; Schuster, Stephen J. (Perelman Center for Advanced Medicine) ; Schuh, Anna (University of Oxford) ; Gill, Devinder (Princess Alexandra Hospital) ; Bloor, Adrian (The Christie Clinic) ; Dearden, Claire (The Royal Marsden Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cull, Gavin (Sir Charles Gardiner Hospital) ; Hamblin, Mike (Colchester Hospital) ; Jones, Jeffrey A. (The Ohio State University Comprehensive Cancer Center) ; Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Suzuki, Samuel (Pharmacyclics LLC. an AbbVie Company) ; Hsu, Emily (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James University Hospital) ; Universitat Autònoma de Barcelona
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. [...]
2018 - 10.1016/j.clml.2018.08.007
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 12 (december 2018) , p. 803-813.e7  
352.
9 p, 1.3 MB Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies / Robak, Tadeusz (Medical University of Lodz) ; Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Barr, Paul M. (University of Rochester Cancer Center) ; Owen, Carolyn (University of Calgary) ; Bairey, Osnat (Tel Aviv University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Simpson, David (North Shore Hospital) ; Grosicki, Sebastian (Silesian Medical University) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Quach, Hang (St. Vincent's Hospital) ; Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ; Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ; Stevens, Don A. (Norton Cancer Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gill, Devinder S. (Princess Alexandra Hospital) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Gribben, John G. (Queen Mary University of London) ; Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410  
353.
6 p, 657.1 KB Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation : A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study / Paviglianiti, Annalisa (Centre Scientifique de Monaco) ; Tozatto Maio, Karina (Centre Scientifique de Monaco) ; Rocha, Vanderson (Hospital Sao Paulo) ; Gehlkopf, Eve (CHU Lapeyronie) ; Milpied, Noel (CHU Bordeaux) ; Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ; Chevallier, Patrice (Hospital Hotel Dieu (Nantes, França)) ; Blaise, Didier (Institute Paoli Calmettes) ; Gac, Anne-Claire (Institut d'Hématologie de Basse-Normandie) ; Leblond, Véronique (Hopital la Pitié-Salpêtrière) ; Cahn, Jean-Yves (CHU Grenoble Alpes) ; Abecasis, Manuel (Institute Portugues Oncologia) ; Zuckerman, Tsila (Rambam Medical Center) ; Schouten, Harry (University Hospital Maastricht) ; Gurman, Gunhan (Ankara University) ; Rubio, Marie Thérèse (Hôpitaux des Brabois) ; Beguin, Yves (CHU of Liège and University of Liege) ; Corral, Lucia Lopez (Centro de Investigacion del Cancer-IBMCC) ; Nagler, Amon (Chaim Sheba Medical Center (Israel)) ; Snowden, John A. (Sheffield Teaching Hospitals NHS Trust) ; Koc, Yener (Stem Cell Transplant Unit Medical Park Hospitals) ; Mordini, Nicola (Az. Ospedaliera S. Croce e Carle) ; Bonifazi, Francesca ("Seragnoli" University Hospital S. Orsola-Malpighi) ; Volt, Fernanda (Centre Scientifique de Monaco) ; Kenzey, Chantal (Centre Scientifique de Monaco) ; Robinson, Stephen Paul (EBMT Lymphoma Working Party) ; Montoto, Silvia (EBMT Lymphoma Working Party) ; Gluckman, Eliane (Centre Scientifique de Monaco) ; Ruggeri, Annalisa (Bambin Gesù) ; Universitat Autònoma de Barcelona
Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma (HL), but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. [...]
2018 - 10.1016/j.bbmt.2018.07.019
Biology of Blood and Marrow Transplantation, Vol. 24 Núm. 11 (november 2018) , p. 2265-2270  
354.
10 p, 1.1 MB Effects of positive end-expiratory pressure strategy in supine and prone position on lung and chest wall mechanics in acute respiratory distress syndrome / Mezidi, Mehdi (Université de Lyon) ; Parrilla-Gómez, Francisco José (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Yonis, Hodane (Hospices Civils de Lyon) ; Riad, Zakaria (Hospices Civils de Lyon) ; Böhm, Stephan H. (Rostock University Medical Center) ; Waldmann, Andreas D. (Witten/Herdecke University Hospital) ; Richard, Jean-Christophe (Université de Lyon) ; Lissonde, Floriane (Hospices Civils de Lyon) ; Tapponnier, Romain (Hospices Civils de Lyon) ; Baboi, Loredana (Hospices Civils de Lyon) ; Mancebo, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Guérin, Claude (INSERM 955) ; Universitat Autònoma de Barcelona
In acute respiratory distress syndrome (ARDS) patients, it has recently been proposed to set positive end-expiratory pressure (PEEP) by targeting end-expiratory transpulmonary pressure. This approach, which relies on the measurement of absolute esophageal pressure (Pes), has been used in supine position (SP) and has not been investigated in prone position (PP). [...]
2018 - 10.1186/s13613-018-0434-2
Annals of Intensive Care, Vol. 8 Núm. 1 (january 2018) , p. 86  
355.
13 p, 429.7 KB Association between gestational weight gain, gestational diabetes risk, and obstetric outcomes : A randomized controlled trial post hoc analysis / Simmons, David (Western Sydney University) ; Devlieger, Roland (GasthuisZusters Antwerpen Sint-Augustinus) ; van Assche, Andre (KU Leuven) ; Galjaard, Sander (University Medical Centre Rotterdam) ; Corcoy i Pla, Rosa (Institut d'Investigació Biomèdica Sant Pau) ; Adelantado, Juan M (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Dunne, Fidelma (National University of Ireland) ; Desoye, Gernot (Medizinische Universitaet Graz) ; Kautzky-Willer, Alexandra (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Damm, Peter (University of Copenhagen) ; Mathiesen, Elisabeth R. (University of Copenhagen) ; Jensen, Dorte M. (University of Southern Denmark) ; Andersen, Lise Lotte T. (University of Southern Denmark) ; Lapolla, Annunziata (Università degli Studi di Padova) ; Dalfra, Maria Grazia (Università degli Studi di Padova) ; Bertolotto, Alessandra (University of Pisa) ; Wender-Ozegowska, Ewa (Poznan University of Medical Sciences) ; Zawiejska, Agnieszka (Poznan University of Medical Sciences) ; Hill, David (Recherche en Santé Lawson SA) ; Snoek, Frank J. (Vrije Universiteit Amsterdam) ; van Poppel, M.N.M (University of Graz) ; Universitat Autònoma de Barcelona
Excess gestational weight gain (GWG) is associated with the development of gestational diabetes mellitus (GDM). Lifestyle trials have not achieved much GWG limitation, and have largely failed to prevent GDM. [...]
2018 - 10.3390/nu10111568
Nutrients, Vol. 10 Núm. 11 (november 2018) , p. 1568  
356.
12 p, 2.4 MB The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients / Taberna, Miren (Hospital Universitari de Bellvitge) ; Torres, Montserrat (Hospital Universitari de Bellvitge) ; Alejo, María (Hospital General de l'Hospitalet) ; Mena, Marisa (Centro de Investigación Biomédica en Red de Cáncer) ; Tous, Sara (Centro de Investigación Biomédica en Red de Cáncer) ; Marquez, Sandra (Hospital Universitari de Bellvitge) ; Pavón, Miquel A. (Hospital Universitari de Bellvitge) ; León, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Garcia Lorenzo, J (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Guix, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Hijano, Rafael (Hospital del Mar (Barcelona, Catalunya)) ; Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Aguilà, Antón (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Lozano, Alicia (Hospital Universitari de Bellvitge) ; Mesía, Ricard (Hospital Universitari de Bellvitge) ; Alemany, Laia (Hospital Universitari de Bellvitge) ; Bravo, Ignacio G. (Laboratory MIVEGEC (CNRS IRD Uni Montp)) ; Universitat Autònoma de Barcelona
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. [...]
2018 - 10.3389/fonc.2018.00589
Frontiers in Oncology, Vol. 8 Núm. DEC (2018) , p. 589  
357.
25 p, 1.7 MB Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma / O'Brien, Susan (University of California) ; Hillmen, Peter (St. James University Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Barr, Paul M (University of Rochester Cancer Center) ; Fraser, Graeme (McMaster University (Canadà)) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ; Hess, Georg (Universitats Medizin Mainz) ; Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cramer, Paula (University of Cologne) ; Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ; Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ; Vermeulen, Jessica (Janssen Research & Development) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; Howes, Angela (Janssen Research & Development) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ; Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ; Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ; Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15  
358.
10 p, 271.5 KB Patient self-reported adherence to ritonavir-boosted darunavir combined with either raltegravir or tenofovir disoproxil fumarate/emtricitabine in the NEAT001/ANRS143 Trial / Ammassari, Adriana (IRCCS) ; Stöhr, Wolfgang (Medical Research Council Clinical Trials Unit at UCL) ; Antinori, Andrea (IRCCS) ; Molina, Jean-Michel (University of Paris Diderot) ; Schwimmer, Christine (University of Bordeaux) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Thalme, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Di Pietro, Massimo (S. Maria Annunziata Hospital) ; Wallet, Cedrik (University of Bordeaux) ; Pozniak, Anton (Chelsea and Westminster NHS Trust St Stephens Centre) ; Richert, Laura (University of Bordeaux) ; Raffi, François (INSERM CIC 1413. CHU) ; Universitat Autònoma de Barcelona
NEAT001/ANRS143 trial demonstrated noninferiority of ritonavir-boosted darunavir combined with either raltegravir (RAL + DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC + DRV/r) in HIV-positive, antiretroviral-naive adults. [...]
2018 - 10.1097/QAI.0000000000001834
Journal of Acquired Immune Deficiency Syndromes, Vol. 79 Núm. 4 (2018) , p. 481-490  
359.
5 p, 535.8 KB Towards a policy relevant neighborhoods and health agenda : engaging citizens, researchers, policy makers and public health professionals. SESPAS Report 2018 Por una estrategia de barrios saludables políticamente relevante: colaboración entre ciudadanía, personas investigadoras, decisoras políticas y profesionales de la salud pública. Informe SESPAS 2018 / Franco, Manuel (Johns Hopkins Bloomberg School of Public Health) ; Díez, Julio (Universidad de Alcalá) ; Gullón, Pedro (Universidad de Alcalá) ; Margolles, Mario (Instituto de Investigación Sanitaria del Principado de Asturias) ; Cofiño, Rafael (Escuela Andaluza de Salud Pública) ; Pasarín, Maribel (Institut d'Investigació Biomèdica Sant Pau) ; Borrell i Thió, Carme (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
A large volume of public health literature has shown how the social and physical features of a neighbourhood affect residents' health, and how they contribute to health inequalities. In this article, we argue that citizens, researchers, policy makers and health professionals should engage in creating a common, policy-relevant neighbourhood and health agenda to effectively improve population health and reduce health inequalities. [...]
2018 - 10.1016/j.gaceta.2018.07.002
Gaceta sanitaria, Vol. 32 (octubre 2018) , p. 69-73  
360.
17 p, 345.4 KB Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up / Casali, P.G. (University of Milan) ; Bielack, Stefan S (Klinikum Stuttgart-Olgahospital) ; Abecassis, N. (Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE) ; Aro, H.T. (Turku University Hospital (Turun Yliopistollinen Keskussairaala)) ; Bauer, S. (University Hospital Essen (Alemanya)) ; Biagini, Roberto (Regina Elena National Cancer Institute) ; Bonvalot, S. (Institut Curie) ; Boukovinas, I. (Bioclinic Thessaloniki) ; Bovee, J.V.M.G. (Leiden University Medical Center) ; Brennan, B. (Royal Manchester Children's Hospital) ; Brodowicz, Thomas (Medizinische Universität Wien) ; Broto, J.M. (Hospital Universitario Virgen Del Rocio-CIBERONC) ; Brugières, L. (Gustave Roussy Cancer Campus) ; Buonadonna, A. (Centro di Riferimento Oncologico di Aviano) ; De Alava, E (Universidad de Sevilla) ; Dei Tos, A.P. (Ospedale Regionale di Treviso S.Maria di Cà Foncello) ; Del Muro, X.G. (Integrated Unit ICO Hospitalet) ; Dileo, P. (University College London Hospitals NHS Trust) ; Dhooge, C. (Universitair Ziekenhuis Gent) ; Eriksson, M. (Skåne University Hospital (Suècia)) ; Fagioli, F. (University of Turin) ; Fedenko, A. (N. N. Blokhin Russian Cancer Research Center) ; Ferraresi, V. (Regina Elena National Cancer Institute) ; Ferrari, A. (Fondazione IRCCS Istituto Nazionale Dei Tumori) ; Ferrari, S. (Istituto Ortopedico Rizzoli) ; Frezza, A.M. (Istituto Nazionale Dei Tumori) ; Gaspar, N. (Gustave Roussy Cancer Campus) ; Gasperoni, S. (Azienda Ospedaliera Universitaria Careggi Firenze) ; Gelderblom, H. (Leiden University Medical Centre) ; Gil, T. (Institut Jules Bordet) ; Grignani, G. (Candiolo Cancer Institute) ; Gronchi, A. (University of Milan) ; Haas, R.L. (Leiden University Medical Centre) ; Hassan, B. (Oxford University Hospitals NHS Foundation Trust) ; Hecker-Nolting, S. (Klinikum Stuttgart-Olgahospital) ; Hohenberger, P. (Mannheim University Medical Center) ; Issels, R. (University Munich) ; Joensuu, H. (Helsinki University Central Hospital (HUCH)) ; Jones, R.L. (Royal Marsden Hospital (Regne Unit)) ; Judson, I. (Institute of Cancer Research) ; Jutte, P. (University Medical Center Groningen) ; Kaal, S. (Radboud University Medical Center) ; Kager, L. (St. Medical University Vienna) ; Kasper, B. (Mannheim University Medical Center) ; Kopeckova, K. (University Hospital Motol) ; Krákorová, D.A. (Masaryk Memorial Cancer Institute) ; Ladenstein, R. (Medical University Vienna) ; Le Cesne, A. (Gustave Roussy Cancer Campus) ; López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; Lugowska, I. (Maria Skłodowska Curie Institute-Oncology Centre) ; Merimsky, O. (Tel Aviv Sourasky Medical Center (Ichilov)) ; Montemurro, M. (Medical Oncology University Hospital of Lausanne) ; Morland, B. (Birmingham Women's and Children's NHS Foundation Trust) ; Pantaleo, M.A. (Policlinico S Orsola-Malpighi Università di Bologna) ; Piana, R. (University of Turin) ; Picci, P. (Istituto Ortopedico Rizzoli) ; Piperno-Neumann, S. (Institut Curie) ; Reichardt, P. (Helios Klinikum Berlin Buch) ; Robinson, M.H. (Weston Park Hospital NHS Trust) ; Rutkowski, P. (Maria Skłodowska Curie Institute-Oncology Centre) ; Safwat, A.A. (Aarhus University Hospital (Aarhus, Dinamarca)) ; Schöffski, P. (University Hospitals Leuven (Bèlgica)) ; Sleijfer, S. (Erasmus MC Cancer Institute) ; Stacchiotti, S. (Istituto Nazionale Dei Tumori) ; Strauss, S.J. (University College London Hospitals NHS Trust) ; Sundby Hall, K. (Norwegian Radium Hospital) ; Unk, M. (Institute of Oncology of Ljubljana) ; Van Coevorden, F. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ; Van Der Graaf, W.T.A. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ; Whelan, J. (Sarcoma Unit. University College London Hospitals NHS Trust) ; Wardelmann, E. (Universitätsklinikum Münster) ; Zaikova, O. (Oslo University Hospital (Oslo, Noruega)) ; Blay, Jean-Yves (Centre Leon Bernard and UCBL1) ; Universitat Autònoma de Barcelona
2018 - 10.1093/annonc/mdy310
Annals of oncology, Vol. 29 (january 2018) , p. iv79-iv95  

Articles : 5,464 registres trobats   inicianterior351 - 360següentfinal  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.